JPS5592315A - Remedy for cataract - Google Patents

Remedy for cataract

Info

Publication number
JPS5592315A
JPS5592315A JP90579A JP90579A JPS5592315A JP S5592315 A JPS5592315 A JP S5592315A JP 90579 A JP90579 A JP 90579A JP 90579 A JP90579 A JP 90579A JP S5592315 A JPS5592315 A JP S5592315A
Authority
JP
Japan
Prior art keywords
cataract
remedy
cysteine
administration
ointnent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP90579A
Other languages
Japanese (ja)
Other versions
JPS6213922B2 (en
Inventor
Junichi Iwao
Takehisa Chiba
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Santen Pharmaceutical Co Ltd
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Priority to JP90579A priority Critical patent/JPS5592315A/en
Publication of JPS5592315A publication Critical patent/JPS5592315A/en
Publication of JPS6213922B2 publication Critical patent/JPS6213922B2/ja
Granted legal-status Critical Current

Links

Abstract

PURPOSE: A remedy for cataract with low toxicity, comprising a specific cysteine derivative or its slat as an active constituent.
CONSTITUTION: A remedy comprising a compound of the formula (A is 1W3C alkylene group), e.g. 3-mercaptopropionyl-L-cysteine, or its salt, known as a sputum dissolving agent. The remedy has a crisis retarding and cataract remedial effects, i.e. clarifying the opacity of the crystalline lens due to the cataract. The dose is 10W1,000mg per day and adult by general administration, e.g. oral route subcutaneous or intravenous injection, or as a 0.1W10% eye drop or opthalmic ointnent due to the local administration.
COPYRIGHT: (C)1980,JPO&Japio
JP90579A 1979-01-05 1979-01-05 Remedy for cataract Granted JPS5592315A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP90579A JPS5592315A (en) 1979-01-05 1979-01-05 Remedy for cataract

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP90579A JPS5592315A (en) 1979-01-05 1979-01-05 Remedy for cataract

Publications (2)

Publication Number Publication Date
JPS5592315A true JPS5592315A (en) 1980-07-12
JPS6213922B2 JPS6213922B2 (en) 1987-03-30

Family

ID=11486687

Family Applications (1)

Application Number Title Priority Date Filing Date
JP90579A Granted JPS5592315A (en) 1979-01-05 1979-01-05 Remedy for cataract

Country Status (1)

Country Link
JP (1) JPS5592315A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3643119A1 (en) * 1985-11-27 1988-06-23 Senju Pharma Co THERAPEUTIC COMPOSITION FOR DIABETES COMPLICATIONS
WO1994003167A1 (en) * 1992-08-01 1994-02-17 Santen Pharmaceutical Co., Ltd. Cataract remedy
US5519054A (en) * 1991-02-21 1996-05-21 Zambon Group S.P.A. Pharmaceutical compositions containing N-acetyl-cysteine derivatives useful for the treatment of cataract
WO1999034795A1 (en) * 1998-01-09 1999-07-15 Santen Pharmaceutical Co., Ltd. Neovascularization inhibitors

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3643119A1 (en) * 1985-11-27 1988-06-23 Senju Pharma Co THERAPEUTIC COMPOSITION FOR DIABETES COMPLICATIONS
US4794124A (en) * 1985-11-27 1988-12-27 Senju Pharmaceutical Co., Ltd. Therapeutic composition for diabetic complications
US5519054A (en) * 1991-02-21 1996-05-21 Zambon Group S.P.A. Pharmaceutical compositions containing N-acetyl-cysteine derivatives useful for the treatment of cataract
WO1994003167A1 (en) * 1992-08-01 1994-02-17 Santen Pharmaceutical Co., Ltd. Cataract remedy
WO1999034795A1 (en) * 1998-01-09 1999-07-15 Santen Pharmaceutical Co., Ltd. Neovascularization inhibitors

Also Published As

Publication number Publication date
JPS6213922B2 (en) 1987-03-30

Similar Documents

Publication Publication Date Title
JPS5671073A (en) Imidazole derivative
JPS5671074A (en) 1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
IT1264923B1 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF HEPATITIS B (HBV) VIRUS INFECTION
NO943093L (en) Process for the preparation of clavulanic acid
EP0132764A3 (en) New compounds derived from diphenyl-methylene-ethylamine
JPS5551020A (en) Remedy for rheumatism
JPS5592315A (en) Remedy for cataract
FI903692A0 (en) SALTER AV N5, N10-METHYLENE-5,6,7,8-TETRAHYDROPHOLSYRA.
ES8607973A1 (en) Amino-lower-alkyl-penem derivatives, process for their preparation, pharmaceutical compositions containing them and their use.
JPS5347515A (en) Gamma-globulin pharmaceutical preparation for intravenous injection
AU658175B2 (en) Use of 2-iminothiazolidin-4-one derivatives as novel pharmaceutical active ingredients
ES8300755A1 (en) Imidazole derivatives, their preparation and pharmaceutical compositions containing them.
JPS5513241A (en) Remedy for glaucoma
IE45096L (en) Thiadiazole derivatives
ATE29133T1 (en) TROPONONE DERIVATIVES, PROCESS FOR THEIR MANUFACTURE AND PHARMACEUTICAL COMPOSITION CONTAINING THEM.
JPS55102516A (en) Remedy for glaucoma
JPS5716842A (en) Substance related to bestatin and its preparation
GB1468079A (en) Ethanolamine derivatives
JPS5718615A (en) Anticataract agent
JPS54125663A (en) Carcinostatic agent and novel compound having carcinostatic activity
JPS5569510A (en) Carcinostatic agent
IE39639L (en) Preparation of n-substituted cycloserine derivatives.
JPS5569569A (en) Carcinostatic
JPS57126422A (en) Stabilizing method of lysozyme pharmaceutical
JPS57128625A (en) Carcinostatic